RU2006132352A - Кристаллическая полиморфная форма базедоксифен ацетата - Google Patents

Кристаллическая полиморфная форма базедоксифен ацетата Download PDF

Info

Publication number
RU2006132352A
RU2006132352A RU2006132352/04A RU2006132352A RU2006132352A RU 2006132352 A RU2006132352 A RU 2006132352A RU 2006132352/04 A RU2006132352/04 A RU 2006132352/04A RU 2006132352 A RU2006132352 A RU 2006132352A RU 2006132352 A RU2006132352 A RU 2006132352A
Authority
RU
Russia
Prior art keywords
approximately
polymorphic form
mixture
bazedoxifene acetate
composition
Prior art date
Application number
RU2006132352/04A
Other languages
English (en)
Russian (ru)
Inventor
Кадум А. АЛИ (US)
Кадум А. Али
Пиетро АЛЛЕГРИНИ (IT)
Пиетро АЛЛЕГРИНИ
Алдо БЕЛЛИ (IT)
Алдо БЕЛЛИ
Роберто БРЕСЧЕЛЛО (IT)
Роберто БРЕСЧЕЛЛО
Виченцо КАННАТА (IT)
Виченцо КАННАТА
Малама К. ЧИБВЕ (US)
Малама К. Чибве
Ливиус КОТАРКА (IT)
Ливиус Котарка
Шридхар Г. ГАНГОЛИ (US)
Шридхар Г. ГАНГОЛИ
Карл Е. ЛОНГФЕЛЛОУ (US)
Карл Е. Лонгфеллоу
Джорджио СОРИАТО (IT)
Джорджио Сориато
Массимо ВЕРЦИНИ (IT)
Массимо Верцини
Original Assignee
Вайет (Us)
Вайет
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=34965585&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=RU2006132352(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Вайет (Us), Вайет filed Critical Вайет (Us)
Publication of RU2006132352A publication Critical patent/RU2006132352A/ru

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
    • C07D209/04—Indoles; Hydrogenated indoles
    • C07D209/10—Indoles; Hydrogenated indoles with substituted hydrocarbon radicals attached to carbon atoms of the hetero ring
    • C07D209/12—Radicals substituted by oxygen atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/08—Drugs for genital or sexual disorders; Contraceptives for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/12—Drugs for genital or sexual disorders; Contraceptives for climacteric disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/14—Drugs for dermatological disorders for baldness or alopecia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
    • A61P5/30—Oestrogens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
    • A61P5/32—Antioestrogens

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Endocrinology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Reproductive Health (AREA)
  • Rheumatology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Diabetes (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Psychiatry (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Hospice & Palliative Care (AREA)
  • Dermatology (AREA)
  • Gynecology & Obstetrics (AREA)
  • Pregnancy & Childbirth (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Steroid Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Indole Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
RU2006132352/04A 2004-04-07 2005-04-06 Кристаллическая полиморфная форма базедоксифен ацетата RU2006132352A (ru)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US56058404P 2004-04-07 2004-04-07
US60/560,584 2004-04-07

Publications (1)

Publication Number Publication Date
RU2006132352A true RU2006132352A (ru) 2008-05-20

Family

ID=34965585

Family Applications (1)

Application Number Title Priority Date Filing Date
RU2006132352/04A RU2006132352A (ru) 2004-04-07 2005-04-06 Кристаллическая полиморфная форма базедоксифен ацетата

Country Status (20)

Country Link
US (1) US7683052B2 (cg-RX-API-DMAC7.html)
EP (1) EP1732889A1 (cg-RX-API-DMAC7.html)
JP (2) JP2007532548A (cg-RX-API-DMAC7.html)
KR (1) KR20070004815A (cg-RX-API-DMAC7.html)
CN (1) CN1938271A (cg-RX-API-DMAC7.html)
AR (1) AR048683A1 (cg-RX-API-DMAC7.html)
AU (1) AU2005233114A1 (cg-RX-API-DMAC7.html)
BR (1) BRPI0509257A (cg-RX-API-DMAC7.html)
CA (1) CA2561296A1 (cg-RX-API-DMAC7.html)
EC (1) ECSP066910A (cg-RX-API-DMAC7.html)
GT (1) GT200500080A (cg-RX-API-DMAC7.html)
IL (1) IL178101A0 (cg-RX-API-DMAC7.html)
NO (1) NO20065046L (cg-RX-API-DMAC7.html)
PA (1) PA8629201A1 (cg-RX-API-DMAC7.html)
PE (1) PE20060173A1 (cg-RX-API-DMAC7.html)
RU (1) RU2006132352A (cg-RX-API-DMAC7.html)
TW (1) TW200536845A (cg-RX-API-DMAC7.html)
UA (1) UA86055C2 (cg-RX-API-DMAC7.html)
WO (1) WO2005100314A1 (cg-RX-API-DMAC7.html)
ZA (1) ZA200608361B (cg-RX-API-DMAC7.html)

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20070003623A1 (en) * 2005-06-29 2007-01-04 Wyeth Formulations of conjugated estrogens and bazedoxifene
CN101304731B (zh) * 2005-08-24 2012-06-20 惠氏公司 醋酸苯卓昔芬制剂及其生产方法
PE20090100A1 (es) * 2007-03-30 2009-02-26 Wyeth Corp Metodos de separacion y deteccion de acetato de bacedoxifeno en composiciones farmaceuticas
CZ302358B6 (cs) * 2007-07-25 2011-03-30 Zentiva, A. S. Nové soli bazedoxifenu
EP2252585B1 (en) * 2008-02-11 2013-11-06 Wyeth LLC Methods of preparing polymorphic form a of bazedoxifene acetate
US20100016290A1 (en) * 2008-02-11 2010-01-21 Livius Cotarca Amorphous polymorph of bazedoxifene acetate
ITMI20091109A1 (it) * 2009-06-23 2010-12-24 Wyeth Corp Forma polimorfa d di bazedoxifene acetato e metodi per la sua preparazione
EP2493477B1 (en) 2009-10-27 2013-10-16 Wyeth LLC Bazedoxifene formulations with antioxidants
WO2012007453A1 (en) 2010-07-14 2012-01-19 Sandoz Ag Crystalline compound of 1-[4-(2-azepan-1-ylethoxy)benzyl]-2-(4-hydroxyphenyl)-3-methyl-1h-indol-5-ol
EP2407467A1 (de) 2010-07-14 2012-01-18 Sandoz Ag Kristalline Verbindung von 1-[4-(2-azepan-1-yl-ethoxy)-benzyl]-2-(4-hydroxyphenyl)-3-methyl-1H-indol-5-ol und Milchsäure
US9212172B2 (en) 2010-09-14 2015-12-15 Dr. Reddy's Laboratories Limited Preparation of crystalline bazedoxifene and its salts
EP2471770A1 (en) 2010-12-28 2012-07-04 Sandoz Ag Method of preparing polymorphic pure form A of bazedoxifene acetate
CN103864664A (zh) * 2012-12-18 2014-06-18 江苏柯菲平医药有限公司 巴多昔芬乙酸盐新晶型及其制备方法
WO2014186325A1 (en) 2013-05-15 2014-11-20 Indiana University Research And Technology Corporation Processes and intermediates for preparing indole pharmaceuticals
CN103864665B (zh) * 2014-03-04 2016-03-02 苏州特瑞药业有限公司 醋酸巴多昔芬的制备方法
CN104030963A (zh) * 2014-06-30 2014-09-10 四川大学 一种巴多昔芬醋酸盐晶型a的制备方法
CN111004165A (zh) * 2019-12-03 2020-04-14 南京正济医药研究有限公司 一种醋酸巴多昔芬晶型a的制备方法
US11246874B1 (en) 2021-04-20 2022-02-15 Oxygen Biotech LLC Treatment of COVID-19

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5780497A (en) 1996-04-19 1998-07-14 American Home Products Corporation 2-phenyl-1- 4-(amino-1-yl-alk-1-ynyl)-benzyl!-1H-indol-5-ols as estrogenic agents
TW397821B (en) 1996-04-19 2000-07-11 American Home Produits Corp 3-[4-(2-phenyl-indole-1-ylmethyl)-phenyl]-acrylamides and 2-phenyl-1-[4-(amino-1-yl-alk-1-ynyl)-benzyl]-1H-indol-5-ol as well as pharmaceutical compositions of estrogenic agents thereof
US5998402A (en) 1996-04-19 1999-12-07 American Home Products Corporation 2-phenyl-1-[4-(2-aminoethoxy)-benzyl]-indoles as estrogenic agents
SK281737B6 (sk) 1996-04-19 2001-07-10 American Home Products Corporation 2-fenylindolové zlúčeniny, farmaceutický prostriedok s ich obsahom a ich použitie
US5880137A (en) 1996-04-19 1999-03-09 American Home Products Corporation 2-phenyl-1- 4-(amino-1-yl-alk-1-ynyl)-benzyl!-1H-indol-5-ols as estrogenic agents
US6005102A (en) 1997-10-15 1999-12-21 American Home Products Corporation Aryloxy-alkyl-dialkylamines
PT1025077E (pt) 1997-10-15 2007-05-31 Wyeth Corp Novas ariloxi-alquil-dialquilaminas
US6479535B1 (en) * 1998-05-15 2002-11-12 Wyeth 2-phenyl-1-[4-(2-aminoethoxy)-benzyl]-indole and estrogen formulations
AR029538A1 (es) 2000-07-06 2003-07-02 Wyeth Corp Composiciones farmaceuticas de agentes estrogenicos
EP1336602A1 (en) 2002-02-13 2003-08-20 Giovanni Scaramuzzino Nitrate prodrugs able to release nitric oxide in a controlled and selective way and their use for prevention and treatment of inflammatory, ischemic and proliferative diseases
JP2005535623A (ja) 2002-06-25 2005-11-24 ワイス ホルモン関連症状の治療における、チオ−オキシインドール誘導体の使用
RU2006132180A (ru) 2004-04-07 2008-05-20 Вайет (Us) Кристаллический полиморф базедоксифен ацетата

Also Published As

Publication number Publication date
TW200536845A (en) 2005-11-16
ECSP066910A (es) 2006-12-20
CN1938271A (zh) 2007-03-28
EP1732889A1 (en) 2006-12-20
PE20060173A1 (es) 2006-04-12
PA8629201A1 (es) 2005-11-25
BRPI0509257A (pt) 2007-09-11
GT200500080A (es) 2005-10-31
AU2005233114A1 (en) 2005-10-27
JP2007532548A (ja) 2007-11-15
IL178101A0 (en) 2006-12-31
UA86055C2 (ru) 2009-03-25
ZA200608361B (en) 2010-03-31
NO20065046L (no) 2006-11-06
KR20070004815A (ko) 2007-01-09
WO2005100314A1 (en) 2005-10-27
CA2561296A1 (en) 2005-10-27
US20050250762A1 (en) 2005-11-10
AR048683A1 (es) 2006-05-17
US7683052B2 (en) 2010-03-23
JP2009007361A (ja) 2009-01-15

Similar Documents

Publication Publication Date Title
RU2006132180A (ru) Кристаллический полиморф базедоксифен ацетата
KR101954322B1 (ko) C-met 조절제를 사용하는 방법
CN101130567B (zh) 新的抗雌激素甾族化合物、有关的药学组合物和使用方法
AU2007329895C1 (en) Crystalline form of 1- (beta-D-glucopyranosyl) -4 -methyl- 3- [5- (4 -fluorophenyl) -2-thienylmethyl] benzene hemihydrate
CA2514169A1 (en) Process for obtaining 17.alpha.-acetoxy-11.beta.(4-n,n-dimethylaminophenyl-19-norpregna-4,9-diene-3,20-dione
JP2011511011A5 (cg-RX-API-DMAC7.html)
JPH10505079A (ja) 骨粗鬆症の予防および治療のためのトリフェニルエチレン類
JP2009007361A (ja) バゼドキシフェンアセテートの結晶質多形体
EA021946B1 (ru) (11β,17β)-17-ГИДРОКСИ-11-[4-(МЕТИЛСУЛЬФОНИЛ)ФЕНИЛ]-17-(ПЕНТАФТОРЭТИЛ)ЭСТРА-4,9-ДИЕН-3-ОН И ЛЕКАРСТВЕННОЕ СРЕДСТВО, ЕГО СОДЕРЖАЩЕЕ
JP2007532548A5 (cg-RX-API-DMAC7.html)
JP2025536416A5 (cg-RX-API-DMAC7.html)
RU2006132179A (ru) Состав, содержащий твердую дисперсию базедоксифен ацетата
DE69806473T2 (de) Neue 4-halogenierte steroide, ein verfahren und zwischenprodukten zu ihrer herstellung, ihre verwendung als medikamenten und pharmazeutische zusammensetzungen davon
JPH10511641A (ja) ジアリールエチレンメタロセン誘導体、その製法及びその誘導体を含有する医薬組成物
TW200817370A (en) Process for the preparation of indolin-2-one derivatives useful as pr modulators
NZ336224A (en) Steroids substituted in position 11, method of preparation, application as medicines and pharmaceutical compositions containing them
AU740229B2 (en) Crystalline progestagens
CN117143167A (zh) 一种α晶型尼尔雌醇及其制备方法
JP2003517001A (ja) 芳香族側鎖中にフルオロアルキル基を有する11β−フェニルエストラジエン誘導体、その製造法および該化合物を含有する医薬組成物
CN101863903A (zh) 1,4-二氢噻吩并[3’,2’:5,6]噻喃并[4,3-c]吡唑-3-羧酸衍生物及其应用
ZA200007355B (en) Novel 17-halogenated 19-nor steroids, method and intermediates for preparing same, use as medicines and pharmaceutical compositions containing same.
CN1993351A (zh) 哌多昔芬盐酸盐一水合物的结晶多晶型物
CN1993322A (zh) 哌多昔芬盐酸盐一水合物的结晶多晶型物
MXPA06011717A (en) Crystalline polymorph of bazedoxifene acetate
MXPA06011716A (en) Crystalline polymorph of a bazedoxifene acetate

Legal Events

Date Code Title Description
FA92 Acknowledgement of application withdrawn (lack of supplementary materials submitted)

Effective date: 20091102